Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131

PurposePatients receiving high-dose I-131 to treat differentiated thyroid cancer are isolated from visitors to limit radiation exposure to reasonable levels. The appropriate isolation time is unclear and has not been reported in Korea. The purpose of this study was to estimate the isolation time and investigate the possibility of earlier release from isolation.MethodsThis study was a retrospective analysis of data from 71 patients (10 men and 61 women; mean age, 49 ± 11.1 y) who received 3.7 GBq (47 patients), 5.55 GBq (23 patients), or 7.4 GBq (1 patient) of I-131 between January 2008 and December 2008. The radiation dose was measured with a fixed probe placed inside the isolation room. The total estimated dose equivalent (TEDE) to family members, the time required for the external dose rate to become <0.07 mSv/h, and the time required for whole-body retention to become <1.2 GBq were calculated.ResultsBy the TEDE criterion (<5 mSv), 70 of 71 patients (98.6%) could have been released without isolation. By the external dose rate criterion, 10 of 71 (14.1%) and 60 of 71 patients (84.5%) could have been released without isolation and within 24 h, respectively. With whole-body retention criterion, 19 of 71 (26.8%) and 48 of 71 patients (67.6%) could have been released within 24 h and within 48 h, respectively.ConclusionsAppropriate release times were estimated and compared using different criteria. Most patients could have been released without isolation or within 24 h of radiation treatment.

[1]  Jung-Hyun Yang,et al.  Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. , 2004, Thyroid : official journal of the American Thyroid Association.

[2]  Y. Choi,et al.  Prevalence of Thyroid Cancer at a Medical Screening Center: Pathological Features of Screen-detected Thyroid Carcinomas , 2008, Yonsei medical journal.

[3]  S. Purisch,et al.  Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity , 2008, Journal of Nuclear Medicine.

[4]  M. Tempero,et al.  Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  A. Introduction RELEASE OF PATIENTS ADMINISTERED RADIOACTIVE MATERIALS , 1997 .

[6]  S. Janković,et al.  Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. , 2009, Thyroid : official journal of the American Thyroid Association.

[7]  Carlos D Venencia,et al.  Hospital discharge of patients with thyroid carcinoma treated with 131I. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  M. Schlumberger,et al.  131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.

[9]  M. Pacilio,et al.  Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements , 2005, Nuclear medicine communications.

[10]  M. O'Doherty,et al.  Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid , 1997, European Journal of Nuclear Medicine.

[11]  C. Bal,et al.  Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I. , 2006, Radiation protection dosimetry.